Seroprevalence of antibodies against serogroup C meningococci in England in the postvaccination era.
about
Seroepidemiology: an underused tool for designing and monitoring vaccination programmes in low- and middle-income countriesCorrelation of group C meningococcal conjugate vaccine response with B- and T-lymphocyte activityAge-related immunity to meningococcal serogroup C vaccination: an increase in the persistence of IgG2 correlates with a decrease in the avidity of IgGImmunity against Neisseria meningitidis serogroup C in the Dutch population before and after introduction of the meningococcal c conjugate vaccineUpdated postlicensure surveillance of the meningococcal C conjugate vaccine in England and Wales: effectiveness, validation of serological correlates of protection, and modeling predictions of the duration of herd immunityGlobal practices of meningococcal vaccine use and impact on invasive disease.Seroprevalence of bactericidal, specific IgG antibodies and incidence of meningitis due to group A Neisseria meningitidis by age in Burkina Faso 2008Protecting the herd: the remarkable effectiveness of the bacterial meningitis polysaccharide-protein conjugate vaccines in altering transmission dynamics.Meningococcal conjugate vaccines: optimizing global impact.Seroprevalence of Antibody-Mediated, Complement-Dependent Opsonophagocytic Activity against Neisseria meningitidis Serogroup B in England.Seroprevalence of serum bactericidal antibodies against group W135 and Y meningococci in England in 2009Is a single infant priming dose of meningococcal serogroup C conjugate vaccine in the United Kingdom sufficient?A Seroepidemiological Study of Serogroup A Meningococcal Infection in the African Meningitis BeltPrevalence of serum bactericidal antibody to serogroup C Neisseria meningitidis in England a decade after vaccine introductionAntibody persistence and immune memory 15 months after priming with an investigational tetravalent meningococcal tetanus toxoid conjugate vaccine (MenACWY-TT) in toddlers and young children.Impact of vaccination on meningococcal epidemiologyAbsence of Neisseria meningitidis serogroup C-specific antibodies during the first year of life in the Netherlands: an age group at risk?Meningococcal vaccines and herd immunity: lessons learned from serogroup C conjugate vaccination programs.Immunodeficiencies.MenACWY-TT vaccine for active immunization against invasive meningococcal disease.Evolving meningococcal immunization strategies.Fighting Neisseria meningitidis: past and current vaccination strategies.What Would be the Best Schedule for Prevention of Meningococcal Disease in All Ages? The UK Experience.Polysaccharide-protein conjugate vaccination induces antibody production but not sustained B-cell memory in the human nasopharyngeal mucosa.Induction of salivary antibody levels in Dutch adolescents after immunization with monovalent meningococcal serogroup C or quadrivalent meningococcal serogroup A, C, W and Y conjugate vaccine.
P2860
Q28078813-F513D967-0E5E-4C8E-B1C1-242F8F19C411Q28732187-A8DFC905-39C8-43A7-847A-A868F8C21831Q28741100-BAE1A0EC-FDB8-4F4D-B4FC-FDF06B4CF2CCQ28749695-9CAB3E19-F13E-4165-85E7-E009EC441D04Q33825722-48B944D5-1AB2-4087-BB2B-853957FB262EQ33850840-90C231EC-FEBF-4896-8841-4EF8100DDAA5Q34606343-0D1E231E-2D85-4BD1-B451-0788E6FA29ECQ35048994-8B4A3A0A-3E83-468C-B875-F86BBDC8BDCBQ35547767-6EE0AD49-10FE-4668-AC37-D8C5BAD72F4AQ35548013-BAD71E8B-638F-4901-9716-50A6A5E515E0Q35739057-2E8A70CB-ADE8-4757-B9D4-854859AE7CB6Q35887266-6C236DBE-1223-4BCA-88BE-782D2D08AFC2Q35922578-A2B548DC-0CC4-4994-901E-03A1DE4FFC5BQ36154716-689CAEB4-483F-4716-8EF6-B27170ADFBFDQ36391874-7A37E425-FCF8-4CCB-B3D4-719E247ACB3BQ37130791-CEF5541C-2612-4083-9BE6-5287459E25D2Q37374696-87173C38-D69B-44A3-B317-EF5025A6EB91Q37524027-EFE29C0A-52AC-476C-9AC3-D28F9267DC60Q37626121-3E052DE2-C2D1-490D-B180-1F7E3DF66821Q38028992-A9902120-00AA-47BD-A37F-B57ED5F32D51Q38286082-73960F04-FC18-48E0-B53A-9FECDF40F86AQ38829564-E3E0EA9D-5CAF-405E-A654-5150C8FE42B2Q40778094-C11EF675-E9A3-46A5-9C0C-FA7DB6D4F051Q43876810-4A155FF8-6890-46D9-AA05-3F11B010FB95Q54963381-FCA31DF4-9C81-4DAE-AFFE-652B833A611B
P2860
Seroprevalence of antibodies against serogroup C meningococci in England in the postvaccination era.
description
2008 nî lūn-bûn
@nan
2008年の論文
@ja
2008年論文
@yue
2008年論文
@zh-hant
2008年論文
@zh-hk
2008年論文
@zh-mo
2008年論文
@zh-tw
2008年论文
@wuu
2008年论文
@zh
2008年论文
@zh-cn
name
Seroprevalence of antibodies a ...... nd in the postvaccination era.
@en
type
label
Seroprevalence of antibodies a ...... nd in the postvaccination era.
@en
prefLabel
Seroprevalence of antibodies a ...... nd in the postvaccination era.
@en
P2093
P2860
P356
P1476
Seroprevalence of antibodies a ...... nd in the postvaccination era.
@en
P2093
Ann Holland
Elizabeth Miller
Jamie Findlow
Nick J Andrews
Sarah Frankland
P2860
P304
P356
10.1128/CVI.00279-08
P577
2008-09-30T00:00:00Z